Pacific Biosciences Narrows 2026 Revenue Guidance and Targets Cash Flow Breakeven by 2028
Pacific Biosciences of California (PACB) has provided updated financial guidance, narrowing its projected revenue for 2026 to a range of $155 million to $160 million. The company is also outlining a long-term path toward profitability, aiming to achieve cash flow breakeven by the year 2028. During the Q3 earnings call, management highlighted the successful rollout of SPRQ-Nx chemistry. This new technology has seen rapid adoption, with over half of all Revio consumable revenue now being driven by customers utilizing the SPRQ-Nx platform.
Tickers: $PACB
Topics: consumables earnings call product launch revenue growth
Read the full article at Seeking Alpha
Part of the story MicroVision Reaffirms 2026 Revenue Guidance and Outlines 2027 Cash Burn Targets (11 articles)